CN107847571A - 用于改善多糖‑蛋白质缀合物及其获得的多价疫苗配制剂的吸附的方法 - Google Patents

用于改善多糖‑蛋白质缀合物及其获得的多价疫苗配制剂的吸附的方法 Download PDF

Info

Publication number
CN107847571A
CN107847571A CN201680040596.5A CN201680040596A CN107847571A CN 107847571 A CN107847571 A CN 107847571A CN 201680040596 A CN201680040596 A CN 201680040596A CN 107847571 A CN107847571 A CN 107847571A
Authority
CN
China
Prior art keywords
polysaccharide
protein
conjugate
conjugates
carrier protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680040596.5A
Other languages
English (en)
Chinese (zh)
Inventor
R·M·德尔
H·K·马尔维亚
S·K·嘉娜
S·S·皮萨尔
A·D·马尔雅
S·马霍
M·M·高塔姆
C·V·乔什
V·V·K·马莱帕蒂
P·S·贾达夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serum Institute of India Pvt Ltd
Original Assignee
Serum Institute of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute of India Pvt Ltd filed Critical Serum Institute of India Pvt Ltd
Publication of CN107847571A publication Critical patent/CN107847571A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680040596.5A 2015-06-08 2016-06-03 用于改善多糖‑蛋白质缀合物及其获得的多价疫苗配制剂的吸附的方法 Pending CN107847571A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2185MU2015 2015-06-08
IN2185/MUM/2015 2015-06-08
PCT/IB2016/053265 WO2016199003A1 (en) 2015-06-08 2016-06-03 Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Publications (1)

Publication Number Publication Date
CN107847571A true CN107847571A (zh) 2018-03-27

Family

ID=57503115

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680040596.5A Pending CN107847571A (zh) 2015-06-08 2016-06-03 用于改善多糖‑蛋白质缀合物及其获得的多价疫苗配制剂的吸附的方法

Country Status (17)

Country Link
US (1) US10729780B2 (cg-RX-API-DMAC7.html)
EP (1) EP3302542A4 (cg-RX-API-DMAC7.html)
JP (2) JP7258463B2 (cg-RX-API-DMAC7.html)
KR (2) KR102876828B1 (cg-RX-API-DMAC7.html)
CN (1) CN107847571A (cg-RX-API-DMAC7.html)
AU (2) AU2016276269B2 (cg-RX-API-DMAC7.html)
CA (1) CA2988366C (cg-RX-API-DMAC7.html)
CO (1) CO2017012628A2 (cg-RX-API-DMAC7.html)
EA (1) EA201792470A1 (cg-RX-API-DMAC7.html)
IL (1) IL256118B (cg-RX-API-DMAC7.html)
MX (1) MX2017015985A (cg-RX-API-DMAC7.html)
MY (1) MY187461A (cg-RX-API-DMAC7.html)
PE (1) PE20180460A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017502244A1 (cg-RX-API-DMAC7.html)
SA (1) SA517390495B1 (cg-RX-API-DMAC7.html)
WO (1) WO2016199003A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708325B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110392690A (zh) * 2017-02-24 2019-10-29 默沙东公司 肺炎球菌缀合物疫苗制剂
CN113607939A (zh) * 2021-08-05 2021-11-05 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法
CN115006522A (zh) * 2022-06-16 2022-09-06 北京智飞绿竹生物制药有限公司 一种双价痢疾结合物组合疫苗的制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102143534B1 (ko) 2015-05-04 2020-08-12 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
US10729780B2 (en) * 2015-06-08 2020-08-04 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
CN106822884B (zh) * 2016-12-28 2021-04-30 北京民海生物科技有限公司 一种多价肺炎球菌荚膜多糖结合疫苗的制备方法
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
IL267709B2 (en) 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3074706A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
EP3720483B1 (en) 2017-12-06 2025-11-19 Merck Sharp & Dohme LLC Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN108524926B (zh) * 2018-06-29 2021-06-29 康希诺生物股份公司 一种多价肺炎球菌结合疫苗的制剂组合及其应用
GB201818517D0 (en) * 2018-11-13 2018-12-26 Univ Liverpool John Moores Nanoparticles and uses thereof
EP3897705A2 (en) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3142692A1 (en) * 2019-06-05 2020-12-10 Merck Sharp & Dohme Corp. An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same
US12473379B2 (en) 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
CA3232076A1 (en) * 2023-04-17 2025-04-14 Serum Institute Of India Private Limited Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101378778A (zh) * 2005-12-22 2009-03-04 葛兰素史密丝克莱恩生物有限公司 肺炎球菌多糖缀合物疫苗
CN101500612A (zh) * 2006-04-26 2009-08-05 惠氏公司 使免疫原性组合物稳定且抑制其沉淀的新颖调配物
CN101883583A (zh) * 2007-06-26 2010-11-10 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
CN101926988A (zh) * 2003-01-30 2010-12-29 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
CN103391714A (zh) * 2010-12-10 2013-11-13 默沙东公司 减轻搅动引起的免疫原性组合物聚集的新制剂
CN103893751A (zh) * 2014-03-26 2014-07-02 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
CN104661684A (zh) * 2012-08-16 2015-05-27 辉瑞公司 糖缀合方法和组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
AU2004263135B2 (en) * 2003-08-06 2010-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
EP1871411A4 (en) * 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic EXPRESSION OF HEPATITIS B VIRUS SURFACE ANTIGEN FOR VACCINE MANUFACTURE
WO2007071786A2 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US9198977B2 (en) 2012-01-30 2015-12-01 Serum Institute Of India Ltd. Immunogenic composition
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US10729780B2 (en) * 2015-06-08 2020-08-04 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101926988A (zh) * 2003-01-30 2010-12-29 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
CN101378778A (zh) * 2005-12-22 2009-03-04 葛兰素史密丝克莱恩生物有限公司 肺炎球菌多糖缀合物疫苗
CN101500612A (zh) * 2006-04-26 2009-08-05 惠氏公司 使免疫原性组合物稳定且抑制其沉淀的新颖调配物
CN101883583A (zh) * 2007-06-26 2010-11-10 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
CN103391714A (zh) * 2010-12-10 2013-11-13 默沙东公司 减轻搅动引起的免疫原性组合物聚集的新制剂
CN104661684A (zh) * 2012-08-16 2015-05-27 辉瑞公司 糖缀合方法和组合物
CN103893751A (zh) * 2014-03-26 2014-07-02 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREW LEES等: "Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein—polysaccharide conjugate vaccines and immunological reagents", 《VACCINE》 *
SRINIVAS REDDY CHILUKURI等: "Process development and immunogenicity studies on a serogroup ‘X’ Meningococcal polysaccharide conjugate vaccine", 《BIOLOGICALS》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110392690A (zh) * 2017-02-24 2019-10-29 默沙东公司 肺炎球菌缀合物疫苗制剂
CN110392690B (zh) * 2017-02-24 2024-01-30 默沙东有限责任公司 肺炎球菌缀合物疫苗制剂
US12280107B2 (en) 2017-02-24 2025-04-22 Merck Sharp & Dohme Llc Pneumococcal conjugate vaccine formulations
CN113607939A (zh) * 2021-08-05 2021-11-05 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法
CN113607939B (zh) * 2021-08-05 2024-10-22 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法
CN115006522A (zh) * 2022-06-16 2022-09-06 北京智飞绿竹生物制药有限公司 一种双价痢疾结合物组合疫苗的制备方法

Also Published As

Publication number Publication date
IL256118A (en) 2018-02-28
AU2016276269B2 (en) 2021-01-28
KR20240007690A (ko) 2024-01-16
ZA201708325B (en) 2019-05-29
KR20180030498A (ko) 2018-03-23
MX2017015985A (es) 2018-08-15
NZ738090A (en) 2023-09-29
EP3302542A1 (en) 2018-04-11
US10729780B2 (en) 2020-08-04
WO2016199003A1 (en) 2016-12-15
IL256118B (en) 2021-12-01
JP7258463B2 (ja) 2023-04-17
PE20180460A1 (es) 2018-03-06
KR102876828B1 (ko) 2025-10-27
CA2988366C (en) 2021-12-07
JP2021185152A (ja) 2021-12-09
KR102690378B1 (ko) 2024-08-01
EP3302542A4 (en) 2019-04-10
CO2017012628A2 (es) 2018-03-28
BR112017026343A2 (pt) 2019-11-19
CA2988366A1 (en) 2016-12-15
PH12017502244A1 (en) 2018-06-11
MY187461A (en) 2021-09-23
JP2018516962A (ja) 2018-06-28
AU2024202450A1 (en) 2024-10-31
SA517390495B1 (ar) 2023-03-23
EA201792470A1 (ru) 2018-10-31
AU2016276269A1 (en) 2018-01-18
US20180161445A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
JP7258463B2 (ja) 多糖-タンパク質結合体の吸着およびそれから得られた多価のワクチン製剤を改善するための方法
US10568953B2 (en) Adjuvanting meningococcal factor H binding protein
CN104302315B (zh) 免疫原性组合物及其制备方法
CN102438649A (zh) 脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物
CN103083652B (zh) 一种以异型双功能试剂为连接桥的脑膜炎多糖结合疫苗及其制备方法
CN106659776A (zh) 脑膜炎球菌疫苗
JP2021001182A (ja) ナイセリア・メニンギティディスのワクチン
TW201932140A (zh) 用於改善多糖—蛋白質共軛物及其獲得的多價疫苗配製劑的吸附的方法
CN118806889A (zh) 改善多糖-蛋白质缀合物吸附的方法以及由其获得的多价疫苗制剂
OA19863A (en) Methods for improving the adsorption of polysaccharide-Protein conjugates and multivalent vaccine formulation obtained thereof.
BR112017026343B1 (pt) Métodos para aperfeiçoar a adsorção de conjugados de proteínapolissacarídeo e formulação de vacina multivalente assim obtida
EA040838B1 (ru) Устойчивая поливалентная вакцинная композиция и способ ее получения
WO2025246011A1 (zh) 一种增强重组蛋白抗原免疫原性的方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination